BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 35880178)

  • 1. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
    Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
    Front Immunol; 2022; 13():940688. PubMed ID: 35880178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
    Zhang H; Li S; Feng Y; Zhang Q; Xie B
    Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Primary Biliary Cholangitis including Transplantation.
    Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
    Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
    N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid.
    van Hooff MC; Werner E; van der Meer AJ
    Eur J Intern Med; 2024 Jun; 124():14-21. PubMed ID: 38307734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
    Suraweera D; Rahal H; Jimenez M; Viramontes M; Choi G; Saab S
    Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
    Abbas N; Culver EL; Thorburn D; Halliday N; Crothers H; Dyson JK; Phaw A; Aspinall R; Khakoo SI; Kallis Y; Smith B; Patanwala I; McCune A; Chimakurthi CR; Hegade V; Orrell M; Jones R; Mells G; Thain C; Thain RM; Jones D; Hirschfield G; Trivedi PJ
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1561-1570.e13. PubMed ID: 35961518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
    Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
    Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of fibrates in cholestatic liver diseases.
    Carrion AF; Lindor KD; Levy C
    Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
    Gulamhusein AF; Hirschfield GM
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):93-110. PubMed ID: 31819247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Treatment Strategies for Primary Biliary Cholangitis.
    Parés A
    Semin Liver Dis; 2017 Feb; 37(1):60-72. PubMed ID: 28201850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.